Bellevue Group AG Has $5.88 Million Stake in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)

Bellevue Group AG lifted its stake in shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN) by 1.9% in the 4th quarter, HoldingsChannel.com reports. The fund owned 1,061,753 shares of the company’s stock after acquiring an additional 19,618 shares during the period. Bellevue Group AG’s holdings in Terns Pharmaceuticals were worth $5,882,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the stock. Landscape Capital Management L.L.C. acquired a new stake in Terns Pharmaceuticals in the 4th quarter worth approximately $73,000. Townsquare Capital LLC acquired a new position in Terns Pharmaceuticals in the 4th quarter valued at $76,000. Oxford Asset Management LLP bought a new position in Terns Pharmaceuticals in the 4th quarter worth $86,000. Savant Capital LLC acquired a new position in Terns Pharmaceuticals during the 4th quarter worth $89,000. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in Terns Pharmaceuticals by 33.1% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 18,010 shares of the company’s stock valued at $100,000 after acquiring an additional 4,475 shares during the period. Institutional investors and hedge funds own 98.26% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on TERN shares. William Blair reiterated a “market perform” rating on shares of Terns Pharmaceuticals in a research note on Friday, March 21st. JMP Securities reiterated a “market outperform” rating and set a $20.00 price target on shares of Terns Pharmaceuticals in a report on Monday, April 21st. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat, Terns Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $18.38.

Terns Pharmaceuticals Stock Down 1.7 %

Shares of TERN opened at $3.50 on Friday. The stock’s 50-day moving average price is $2.95 and its 200 day moving average price is $4.74. The firm has a market capitalization of $305.54 million, a price-to-earnings ratio of -2.97 and a beta of -0.13. Terns Pharmaceuticals, Inc. has a 12-month low of $1.87 and a 12-month high of $11.40.

Terns Pharmaceuticals (NASDAQ:TERN) last released its quarterly earnings data on Thursday, March 20th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.06. Equities research analysts expect that Terns Pharmaceuticals, Inc. will post -1.19 EPS for the current year.

Terns Pharmaceuticals Company Profile

Terns Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow.